Physician profile
Eric Jon Eschinger
NPI 1720184625
$6,838.90
in general payments reported to CMS, 2019-2025
37 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $629 · 2021: $195 · 2022: $527 · 2023: $975 · 2024: $1,292 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,003 · Education: $36.20 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.78 |
| Education | $36.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,190.75 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $670.02 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $572.78 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $509.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $307.50 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ferring Pharmaceuticals INC. | $296.22 | 2019-2024 | Rebyota, Cimzia |
| Qol Medical, LLC | $263.49 | 2019-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $222.05 | 2020-2024 | Tremfya |
| Lilly USA, LLC | $177.93 | 2024-2025 | Omvoh, Zepbound |
| Gilead Sciences, INC. | $156.15 | 2019-2025 | Epclusa |
| Genzyme Corporation | $142.41 | 2023-2025 | |
| Celgene Corporation | $127.12 | 2022-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $113.10 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $111.04 | 2019-2024 | |
| Braintree Laboratories, INC. | $103.59 | 2019-2025 | Suflave, Sutab |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Eschinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.